IRES-like pentamer combinatorial translation promoter, multi-gene translatable circular messenger RNA, multi-target nucleic acid drug, and preparation method and application of IRES-like pentamer combinatorial translation promoter and multi-gene translatable circular messenger RNA

By introducing IRES-like pentamer combined translation promoter in circular RNA, cap-independent translation is achieved, and the problems of mRNA drugs in cells are solved, reducing production costs are reduced, and a multi-target The new design idea of ​​pointing nucleic acid drugs has achieved efficient multi-gene translation.

CN119082107APending Publication Date: 2024-12-06NUCLEAR CELL PHARMACEUTICAL R&D (GUANGZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411042653.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing mRNA drugs are unstable in cells and may trigger inflammatory responses, and chemical modifications are complex and costly, making it difficult to effectively solve the challenges of linear mRNA drug production.

Method used

Using IRES-like pentamer combined translation promoter and multigene translateable circular messenger RNA technology, cap-independent translation promoter is achieved by inserting IRES-like pentamer combined translation promoter at the 5' end of the circular RNA sequence, and reducing cap-independent translation Production costs and improve protein expression stability.

Benefits of technology

The organic combination of multi-gene RNA cyclization technology and IRES-like pentamers is realized, and multiple gene products are efficiently translated and synthesized, avoiding the mutations introduced by chemical modification and increasing costs, and providing a new multi-target nucleic acid drug design idea .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082107A_ABST
    Figure CN119082107A_ABST
Patent Text Reader

Abstract

The invention provides an IRES-like pentamer combinatorial translation promoter, a multi-gene translatable annular messenger RNA, a multi-target nucleic acid drug, a preparation method and an application. The promoter can be integrated with a multi-gene RNA cyclization technology; and inserting the multi-gene translatable annular messenger RNA into the 5'end of the annular RNA sequence to obtain the multi-gene translatable annular messenger RNA. According to the present invention, the multiple exogenous mRNA can be converted into the multi-gene translatable annular mRNA without the chemical modification, the multi-gene translatable annular mRNA can be used for research and development of the mRNA protein treatment nucleic acid drug, the synthesis / production time and the economic cost can be reduced, the mutation introduced by the modification can be avoided, the challenge of the difficult drug preparation of the linear mRNA can be solved, and the new design thought can be provided for the preparation of the multi-target nucleic acid drug. The prepared multi-target nucleic acid drug can be introduced into organic somatic cells to efficiently translate and synthesize two or three gene products, so that two or three different proteins deleted in diseases are supplemented at the same time, and the effect of multi-target drug treatment is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of synthetic biomedicine technology, and in particular to an IRES-like pentamer combined translation promoter, a multi-gene translatable circular messenger RNA, a multi-target nucleic acid drug, and a preparation method and application thereof. Background Art

[0002] Except for individual single gene diseases, the occurrence and development of most human diseases, especially chronic diseases, including cardiovascular diseases and cancer, are caused by changes in internal and external factors with multiple factors, multiple levels and multiple mechanisms. However, in many cases, the expression of a key anti-disease factor (protein) is reduced due to inhibition or its function is attenuated due to damage, which can play an inducing or promoting role, thereby causing the corresponding disease to occur (from nothing to something) or accelerating the development of the corresponding disease (from mild to severe).

[0003] There are four strategies to solve this kind of problem: one is to directly increase the expression level of disease-resistant proteins and / or activate the functional level of disease-resistant proteins; the second is to prevent and rescue the downregulation of the expression and loss of function of the disease-resistant proteins; the third is a combination or integration of the first two strategies; and the third is the so-called protein replacement therapy, which is to supplement the proteins that lack function and expression by directly administering proteins, so as to achieve the purpose of eliminating the cause of the disease. The first strategy is usually called protein replacement therapy or supplementation therapy, which is one of the replacement therapies, which is to supplement the missing proteins to the human body; for diseases caused by the lack of a certain protein, it is only necessary to supplement the corresponding exogenous proteins into the human body to play a role in treating the disease.

[0004] However, exogenous proteins are unstable. After entering the human digestive tract, most of them are broken down before entering the blood circulation. Moreover, it is not easy for proteins to penetrate the cell membrane and enter the cell. Moreover, it is quite difficult to produce proteins (biopharmaceuticals) on an industrial scale. There are technical barriers to mass production, complicated procedures, strict process requirements and extremely high costs.

[0005] In recent years, pharmaceutical companies in the United States have taken the lead in successfully developing vaccines against the new coronavirus (vaccines also belong to a class of drugs); the two scholars who won the Nobel Prize in Medicine in 2023 solved one of the key problems that nucleic acids can become drugs, namely, chemical modification of nucleic acids, so that they can be used to treat human diseases. Today, the development of nucleic acid drugs is in full swing and extremely hot. It is regarded as the third wave of new drug development after small molecule compounds and antibody drugs in the history of drug development. At present, pharmaceutical companies in Europe and the United States have turned to focus on the development of new nucleic acid drugs. Among nucleic acid drugs, in addition to small nucleic acid drugs, a more eye-catching category is mRNA drugs. The latter is based on the principle of the central dogma of molecular biology. When a specific exogenous mRNA is delivered into human cells, it can be directly translated into the corresponding protein molecule without going through the gene transcription process and post-transcriptional modification process, supplementing the missing protein, and correcting the pathological process caused by this deficiency. Therefore, it is called mRNA protein replacement therapy.

[0006] Although mRNA drugs represent the most advanced high-tech biopharmaceutical trend of the contemporary era, there are several problems that have not yet been effectively solved: First, both endogenous and exogenous mRNA molecules are linear single-stranded nucleotide structures (although they may have secondary folding structures or even tertiary spatial configurations), which are extremely unstable in cells and can be degraded by RNA enzymes in cells at any time; second, exogenous mRNA molecules can trigger inflammatory immune responses in cells, interfere with and weaken their functions, and may also have harmful effects. Although the stability of mRNA molecules as drugs can be enhanced and their immunogenicity can be weakened through chemical modification, chemical modification itself is not only complicated and costly, but also has a high probability of mutations or coding errors during the translation process in cells, synthesizing proteins with abnormal sequences, which will not only weaken the function of proteins, but also may produce toxic side effects. These problems are still huge challenges that are inevitable in the development of mRNA drugs.

[0007] For linear mRNA, a series of precise and complex design, synthesis and modification steps are usually required. For example, the mRNA vaccines of Moderna and BioNTech both use pseudouracil modification to maintain the stability of mRNA. The purpose of chemical-enzymatic modification is to enhance the stability of mRNA, improve its translation efficiency, and reduce or even avoid immunogenicity. However, chemical modification is quite complicated, and modified mRNA has been shown to produce multiple mutations when translated into corresponding protein molecules in cells, which may cause the translated protein to lose its original biological function and may bring potential toxicity risks. What's more, complex chemical modifications will also greatly increase the production cost of mRNA drugs.

[0008] In order to meet the above challenges, many research teams around the world are thinking about and exploring new mRNA modification methods or alternative technologies. Recently, several studies have found that circular RNAs (circRNAs) can be translated in vivo through different internal ribosome entry sites (IRESs). Because circRNAs lack a 5' end, their translation can only be initiated in a cap-independent mechanism that requires an internal ribosome entry site (IRES). Interestingly, the rolling circle translation of circRNAs obviously produces more protein than circRNAs with stop codons, indicating that the initiation of circRNA translation may be a rate-limiting step because ribosome recycling and restarting are unnecessary for rolling circle translation. Particularly noteworthy is the research of Daniel G. Anderson's team, whose data showed that unmodified exogenous circRNAs can bypass cellular RNA sensors, thereby avoiding immune responses in RIG-I and toll-like receptor (TLR)-competent cells and mice. The immunogenicity and protein expression stability of circRNA preparations depend on purity, and a small amount of contaminated linear RNA can lead to a strong cellular immune response. In vitro, unmodified circRNAs are less immunogenic than unmodified linear mRNAs, in part due to evasion of TLR sensing. Moreover, circRNAs are more robustly translated than unmodified linear mRNAs. Exogenous circRNAs have been shown not to activate cellular RNA sensors, including TLRs and RIG-I. Proteins produced from purified circRNAs are significantly more stable than those produced from unpurified circRNAs, and transfection of purified circRNAs results in cell proliferation. The enhanced expression stability of circRNAs in some tissues and their ability to evade immune sensors without the need for nucleoside modification demonstrate the potential of circRNAs as therapeutic protein expression vectors.

[0009] The internal ribosome entry site is an RNA element that allows the initiation of translation in a cap-independent manner and is a more powerful protein synthesis mechanism. Zefeng Wang's research team recently developed a cell-based reporter system to screen a random library of short sequences that drive circRNA conversion. Through near-saturation screening and subsequent bioinformatics analysis, they identified 97 IRES-like elements hexamers with AU-rich consensus motifs. Compared with all linear RNAs, IRES-like elements are significantly enriched in human circRNAs, suggesting that they are positively selected in the evolution of circRNAs. They further found that almost all open reading frames (ORFs) in circRNAs are likely translated from short IRES-like elements, meaning that most circRNAs may not require additional known IRESs to drive their translation. Summary of the invention

[0010] The present application provides an IRES-like pentamer combined translation promoter, a multi-gene translatable circular messenger RNA, a multi-target nucleic acid drug, and a preparation method and application thereof to solve the problems existing in the related technologies. The technical solution is as follows:

[0011] In a first aspect, an embodiment of the present application provides an IRES-like pentamer combined translation promoter, comprising a first IRES element, a second IRES element, a third IRES element, a fourth IRES element and a fifth IRES element;

[0012] The first IRES element, the second IRES element, the third IRES element, the fourth IRES element and the fifth IRES element are linked by a linker.

[0013] In one embodiment, the sequence of the first IRES element is shown as SEQ ID NO.1;

[0014] The sequence of the second IRES element is shown in SEQ ID NO.2;

[0015] The sequence of the third IRES element is shown in SEQ ID NO.3;

[0016] The sequence of the fourth IRES element is shown in SEQ ID NO.4;

[0017] The sequence of the fifth IRES element is shown as SEQ ID NO.5.

[0018] In one embodiment, the linker is 4 nt in length.

[0019] In one embodiment, the linker is uuug.

[0020] In one embodiment, the sequence of the IRES-like pentamer combined translation promoter is shown as SEQ ID NO.6.

[0021] In a second aspect, an embodiment of the present application provides a multi-gene translatable circular messenger RNA, wherein the translatable circular messenger RNA comprises a circular messenger RNA, and the IRES-like pentamer combined translation promoter according to claim 1 or 2 is inserted before the 5' end of the circular messenger RNA sequence.

[0022] In one embodiment, the translatable circular messenger RNA comprises circular messenger RNA composed of mRNAs of two or more different genes.

[0023] In one embodiment, the number of the different genes is 2 or 3.

[0024] In a third aspect, the present application provides a method for preparing a multi-gene translatable circular messenger RNA, comprising the following steps:

[0025] Select two or more different disease resistance genes as molecular targets according to the pathological mechanism of the target disease;

[0026] According to the mRNA sequence of each of the molecular targets, respectively prepare the corresponding first linear DNA template sequence, and link the IRES-like pentamer combined translation promoter according to claim 1 or 2 to the 5' end of each of the first linear DNA template sequences;

[0027] Two or more first linear DNA template sequences containing IRES-like pentamer combined translation promoters are connected into a second linear DNA template sequence by a linker, and the second linear DNA template sequence is transcribed in vitro to obtain a single linear mRNA; the linear mRNA is cyclized to obtain the multi-gene translatable circular messenger RNA.

[0028] In a fourth aspect, the embodiments of the present application provide the use of the above-mentioned IRES-like pentamer combined translation promoter or the above-mentioned multi-gene translatable circular messenger RNA in the preparation of nucleic acid drugs.

[0029] In a fifth aspect, an embodiment of the present application provides a multi-target nucleic acid drug, comprising the above-mentioned multi-gene translatable circular messenger RNA or the multi-gene translatable circular messenger RNA prepared by the preparation method of the above-mentioned multi-gene translatable circular messenger RNA.

[0030] In one embodiment, the target is heart failure, myocardial infarction, arrhythmia, liver cancer, diabetes or obesity as a target disease target.

[0031] In one embodiment, the multi-target nucleic acid drug is a multi-target nucleic acid drug for treating heart failure, with two or more of ATP2A2, CAND1 or PGC1α as targets.

[0032] In one embodiment, ATP2A2 and CAND1 are used as targets; the multi-target nucleic acid drug for treating heart failure has a structural sequence of IRES-like pentamer combined translation promoter-ATP2A2-IRES-like pentamer combined translation promoter-CAND1.

[0033] In one embodiment, ATP2A2, CAND1 and PGC1α are used as targets, and the nucleic acid drug for treating heart failure has a structural sequence of IRES-like pentamer combined translation promoter-ATP2A2-IRES-like pentamer combined translation promoter-CAND1-IRES-like pentamer combined translation promoter-PGC1α.

[0034] The advantages or beneficial effects of the above technical solution include at least:

[0035] (1) The present invention discloses an IRES-like pentamer-combined translation promoter, which is similar to the IRES carried by typical viruses and can initiate a 5' cap-independent translation process. It can be combined with the polygenic RNA cyclization technology; when inserted before the 5' end of the circular RNA sequence, it can give the circular RNA the function of synthesizing proteins. And for polygenic translatable circular RNA, the IRES-like pentamer-combined translation promoter of the present invention has the best effect of inducing protein translation.

[0036] (2) A multi-gene translatable circular messenger RNA of the present application organically combines the multi-gene RNA cyclization technology and the IRES-like pentamer to obtain a multi-gene translatable circular messenger RNA, which does not require chemical modification, reduces the time and economic cost of synthesis / production, avoids mutations introduced by modification, and solves the challenge of linear mRNA drug development. The organic combination of mRNA cyclization technology and the cap-independent translation mechanism of cyclized mRNA can theoretically convert any multiple exogenous mRNAs into multi-gene translatable circular mRNAs for the development of nucleic acid drugs for mRNA protein therapy, providing a new design idea for the preparation of multi-target nucleic acid drugs.

[0037] (3) A multi-target nucleic acid drug of the present application comprises a multi-gene translatable circular mRNA, which can be efficiently translated and synthesized into two or three gene products after being introduced into the cells of an organism, thereby simultaneously supplementing two or three different proteins that are missing in the disease and obtaining the effect of multi-target drug treatment.

[0038] The above summary is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments and features described above, further aspects, embodiments and features of the present application will be readily apparent by reference to the accompanying drawings and the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] In the accompanying drawings, unless otherwise specified, the same reference numerals throughout the multiple drawings represent the same or similar parts or elements. These drawings are not necessarily drawn to scale. It should be understood that these drawings only depict some embodiments disclosed in the present application and should not be regarded as limiting the scope of the present application.

[0040] Figure 1 This is a graph showing changes in SERCA2a, CAND1 and PGC1α protein levels in cardiomyocytes detected by Western Blot;

[0041] Figure 2 The graph shows the changes in mRNA levels of ATP2A2, CAND1, and PGC1α quantified by qRT-PCR;

[0042] Figure 3 Semi-quantitative graphs of changes in protein levels of SERCA2a, CAND1, and PGC1α were performed for Western blot analysis;

[0043] Figure 4 Representative images of fluorescent immunohistochemical staining showing the delivery efficiency and subcellular distribution of ATP2A2 / TcmRNA, [ATP2A2+CAND1] / TcmRNA, and [ATP2A2+CAND1+PGC1α] / TcmRNAs constructs;

[0044] Figure 5 This is an echocardiographic evaluation of the rescue effect of multi-gene translatable circular RNAs (MG-TcmRNAs) ATP2A2 / TcmRNA, [ATP2A2+CAND1] / TcmRNA, and [ATP2A2+CAND1+PGC1α] / TcmRNA on heart function in mice with heart failure induced by prolonged transverse aortic constriction (TAC);

[0045] Figure 6 Echocardiographic evaluation of the effects of multigene translatable circular RNAs (MG-TcmRNAs) ATP2A2 / TcmRNA, [ATP2A2+CAND1] / TcmRNA, and [ATP2A2+CAND1+PGC1α] / TcmRNA on cardiac contractile function and Ca2+ secretion in mice with heart failure induced by prolonged transverse aortic constriction (TAC) 2+ Impact diagrams of treatments;

[0046] Figure 7 The figure shows the inhibitory effect of multi-gene translatable circular RNA (MG-TcmRNAs) ATP2A2 / TcmRNA, [ATP2A2+CAND1] / TcmRNA and [ATP2A2+CAND1+PGC1α] / TcmRNA on apoptotic cardiomyocyte death;

[0047] Figure 8 This is the TUNEL staining image;

[0048] Fig. 9 Display statistical data graphs for staining;

[0049] Fig.10 Graph showing the rescue effect of multi-gene translatable circular RNA (MG-TcmRNAs) carrying ATP2A2, ATP2A2+CAND1 or ATP2A2+CAND1+PGC1α on impaired cardiac function indicated by ejection fraction (%; EF%) in a mouse model of heart failure (HF) induced by transverse aortic constriction (TAC). DETAILED DESCRIPTION

[0050] In the following, only some exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the present application. Therefore, the drawings and descriptions are considered to be exemplary and non-restrictive in nature.

[0051] The central dogma is an important concept in molecular biology, and can even be said to be the core principle. According to the principle of the central dogma, the genetic material in the cell, or the DNA called the genome, synthesizes messenger RNA (mRNA), that is, RNA that carries genetic information, in units of genes through an enzyme-catalyzed transcription process. Each mRNA carries the genetic information of a gene, that is, the information encoding a protein, which is translated and synthesized into the corresponding protein on the ribosome in the cytoplasm, and the protein is the executor of the gene function. In other words, proteins perform the cell functions defined by their respective genes. Therefore, for diseases caused by the lack of a certain protein, it is only necessary to supplement the corresponding exogenous protein into the human body to play a role in treating the disease.

[0052] The mRNA protein replacement therapy in the prior art is to deliver mRNA drugs (a specific exogenous mRNA) into human cells, and can be directly translated into corresponding protein molecules without going through the gene transcription process and post-transcriptional modification procedures, supplement the missing protein, and correct the pathological process caused by this deficiency. However, exogenous mRNA molecules often need to be chemically modified, and these methods can be roughly divided into three categories: replacing natural RNA with artificially synthesized non-natural RNA to synthesize mRNA; adding 5' caps, 3' poly (A) "tail" UTR (untranslated region) sequences; and using special new formulation technologies to effectively protect mRNA. Among them, replacing natural RNA with artificially synthesized non-natural RNA to synthesize mRNA is one of the more commonly used methods. Chemical modifications on eukaryotic mRNA can be roughly divided into three categories: methylation, pseudouridine (Ψ) and hypoxanthine. After research and industrial application verification, this method can reduce the inherent immunogenicity and instability of mRNA. For example, both Moderna and BioNTech's mRNA vaccines use pseudouracil modification to maintain the stability of mRNA.

[0053] The purpose of chemical-enzymatic modification is to enhance the stability of mRNA, improve its translation efficiency, and reduce or even avoid immunogenicity.

[0054] First, artificial in vitro transcribed (IVT) mRNA is needed, which is structurally similar to the natural mature mRNA of eukaryotic organisms and consists of five main domains - 5' cap, 5' untranslated region, open reading frame encoding the target protein, 3' untranslated region, and Poly (A) tail.

[0055] Secondly, optimization of the untranslated region (UTR) is beneficial to the translation and stability of mRNA. UTR sequences from highly expressed genes, such as the UTR of the human β-globin gene, are widely used in mRNA synthesis because mRNA containing UTRs generally have high levels of translation and stability. The 5' end cap design requires the addition of an m7GPPPN structure to Cap-1. A Poly(A) tail of 100-150 nucleotides in length can improve the stability of mRNA and effectively initiate translation by forming a complex with Poly(A) binding proteins.

[0056] Furthermore, it is necessary to incorporate modified nucleosides, such as pseudouracil (ψ), 5-methylcytidine, N6-methyladenosine, 5-methyluracil, and 2-thiouridine, in order to prevent the recognition of human Toll-like receptors (TLRs) to reduce the production of inflammatory factors and avoid harmful immune responses. It is also necessary to purify the mRNA by high-performance liquid chromatography to ensure that the IVT mRNA does not contain double-stranded RNA (dsRNA) byproducts (protein expression in primary cells is 10-1000 times higher than that of unpurified mRNA) and does not induce the production of IFN or inflammatory cytokines.

[0057] However, this type of chemical modification is often quite complicated and the modified mRNA has been shown to produce multiple mutations when translated into corresponding protein molecules in cells, which may cause the translated protein to lose its original biological function and may bring potential toxicity risks.

[0058] Several recent studies have found that circular RNAs (circRNAs) can be translated in vivo through different internal ribosome entry sites; IRES elements are most commonly found in the 5' untranslated region, but may also occur in other regions within mRNA sequences. Testing of sequences for potential IRES function often relies on the use of bicistronic reporter assays. In these assays, a candidate IRES fragment is introduced into a plasmid between two cistrons encoding two different reporter proteins. A promoter upstream of the first cistron drives transcription of both cistrons in a single mRNA. Cells are transfected with the plasmid, and assays are subsequently performed to quantify the expression of both reporter genes in the cells. An increase in the ratio of expression of the downstream reporter relative to the upstream reporter is taken as evidence of IRES activity in the test sequence. However, without characterization of the mRNA species produced by such plasmids, alternative explanations for this increased ratio cannot be ruled out. For example, there are multiple known cases of suspected IRES elements that were later reported to have promoter function. Unexpected splicing activities within some reported IRES elements have also been shown to be responsible for the apparent IRES function observed in bicistronic reporter assays. The presence of a promoter or splice acceptor in the test sequence results in the production of a monocistronic mRNA, with the downstream cistron initiating translation via conventional cap-dependent rather than IRES-mediated initiation.

[0059] IRES-like pentamers have the ability to initiate 5' cap-independent translation similar to IRES carried by typical viruses, giving circular RNA the ability to synthesize proteins. However, there have been no reports on the rational design of an organic combination of RNA cyclization technology and IRES-like pentamers, especially reports on this organic combination as a potential new strategy or technology for designing nucleic acid drugs.

[0060] The present application embodiment provides an IRES-like pentamer combined translation promoter, including a first IRES element, a second IRES element, a third IRES element, a fourth IRES element and a fifth IRES element;

[0061] The first IRES element, the second IRES element, the third IRES element, the fourth IRES element and the fifth IRES element are linked by a linker.

[0062] There is no report in the prior art on the rational design of organically combining RNA cyclization technology and IRES-like pentamers, especially reports on such organic combination as a potential new strategy or technology for designing multi-target nucleic acid drugs. The present invention provides an IRES-like pentamer combined translation promoter, introduces the concept and technology of "IRES-like pentamer combined translation promoter", and verifies the introduction of IRES-like pentamer combined translation promoter into circular RNA sequence, thereby achieving the preparation of multi-gene translatable circular RNA, and applying multi-gene translatable circular RNA to design new multi-target nucleic acid drugs.

[0063] The IRES-like pentamer combined translation promoter of the present application includes a first IRES element, a second IRES element, a third IRES element, a fourth IRES element and a fifth IRES element; in theory, the more IRES the better; but in practice, the present invention finds that for single-gene translatable circular RNA, when the number of consecutively combined IRES elements reaches 5, the effect of inducing protein translation is close to the optimal state (about 86%), and reaches the optimal state when the number reaches 6. However, for multi-gene translatable circular RNA, when the number of consecutively combined IRES elements reaches 5, the effect of inducing protein translation reaches the optimal state, and further increasing the number does not significantly increase the effect. This is because the two or three groups of IRES-like pentamer combined translation promoters contained in the sequence have positive interaction effects and enhance the translation driving ability. Conversely, if the number of combined IRES elements is less than 5, the effect of inducing protein translation will be greatly reduced, which is an original discovery of the present invention.

[0064] The first IRES element, the second IRES element, the third IRES element, the fourth IRES element and the fifth IRES element are linked by a linker. Two IRES elements are linked by a linker, and the five IRES elements are linked to form an IRES-like pentamer combined translation promoter.

[0065] In one embodiment,

[0066] The sequence of the first IRES element is shown in SEQ ID NO. 1, specifically: AUAAUA;

[0067] The sequence of the second IRES element is shown in SEQ ID NO. 2, specifically: AAUACU;

[0068] The sequence of the third IRES element is shown in SEQ ID NO.3, specifically: AUUAUU;

[0069] The sequence of the fourth IRES element is shown in SEQ ID NO. 4, specifically: AAUAUA;

[0070] The sequence of the fifth IRES element is shown in SEQ ID NO.5, specifically: AAAAUA.

[0071] The present application selects IRES that can bind to the largest number of various factors and other associated factors in the protein translation complex, because these IRES can theoretically interact with a large number of factors in various cells and in different cell states, thereby maximally inducing protein translation. In addition, the present invention has tried to replace the combination we selected with other different IRES, but the effect is not good. And the 5 IRES selected in the present application are the elements with higher frequency in natural circRNA, and can bind to a large number of trans factors that can recognize IRES-like elements, and have higher universality.

[0072] In one embodiment, the linker is 4 nt in length.

[0073] In one embodiment, the linker is uuug.

[0074] The length of the linker in the present application is 4 nt, specifically uuug; when linking, the first IRES element, the second IRES element, the third IRES element, the fourth IRES element and the fifth IRES element are linked to each other with a 4 nt linker; specifically, uuug is used as the linker for connection.

[0075] In one embodiment, the first IRES element, the second IRES element, the third IRES element, the fourth IRES element and the fifth IRES element are linked in sequence with a linker; in this embodiment, the sequence of the IRES-like pentamer combined translation promoter is shown in SEQ ID NO.6, specifically:

[0076] SEQ ID NO.6

[0077] 5'-AUAAUAuuugAAUACUuuugAUUAUUuuugAAUAUAuuugAAAAUA-3'.

[0078] The embodiment of the present application provides a multi-gene translatable circular messenger RNA, wherein the translatable circular messenger RNA comprises a circular messenger RNA, and the IRES-like pentamer combined translation promoter according to claim 1 or 2 is inserted before the 5' end of the circular messenger RNA sequence.

[0079] The present application inserts a group of internal ribosome entry site (IRES) elements before the 5' end of the sequence of each gene in the circularized mRNA (circularized mRNA or cmRNA), so that it has the ability to accurately, quickly and in large quantities translate proteins. The present invention refers to this new type of mRNA as "multi-gene translatable circular messenger RNA (Multi-Gene translatable circular mRNA or MG-TcmRNA)." MG-TcmRNA does not require any chemical modification, so it can reduce the time and economic cost of synthesis / production, avoid mutations that may be introduced due to modification, and solve the challenge of linear mRNA drug development difficulties. The innovation of this technology lies in the organic combination of mRNA circularization technology and the cap-independent translation mechanism of circularized mRNA. In theory, any multiple exogenous mRNAs can be converted into multi-gene translatable circular mRNAs for the development of nucleic acid drugs for mRNA protein therapy, providing a new design idea for the preparation of multi-target nucleic acid drugs.

[0080] In one embodiment, the translatable circular messenger RNA comprises circular messenger RNA composed of mRNAs of two or more different genes.

[0081] In one embodiment, the number of the different genes is 2 or 3.

[0082] In this embodiment, the circular messenger RNA is composed of mRNAs of multiple genes, so the translatable circular messenger RNA is a multi-gene translatable circular messenger RNA, so that the translatable circular messenger RNA can efficiently translate and synthesize multiple gene products, thereby simultaneously supplementing multiple different proteins missing in the disease. Preferably, the number of different genes is 2 or 3. Selecting 2 or 3 genes is optimal in the preparation of translatable circular messenger RNA and the expression of multiple different proteins.

[0083] The present application embodiment provides a method for preparing a multi-gene translatable circular messenger RNA, comprising the following steps:

[0084] Select two or more different disease resistance genes as molecular targets according to the pathological mechanism of the target disease;

[0085] According to the mRNA sequence of each of the molecular targets, respectively prepare the corresponding first linear DNA template sequence, and link the IRES-like pentamer combined translation promoter according to claim 1 or 2 to the 5' end of each of the first linear DNA template sequences;

[0086] Two or more first linear DNA template sequences containing IRES-like pentamer combined translation promoters are connected into a second linear DNA template sequence by a linker, and the second linear DNA template sequence is transcribed in vitro to obtain a single linear mRNA; the linear mRNA is cyclized to obtain the multi-gene translatable circular messenger RNA.

[0087] Two or more different disease resistance genes are selected as molecular targets according to the pathological mechanism of the target disease.

[0088] A specific disease target is selected as the target disease target; for example, targets such as heart failure, myocardial infarction, arrhythmia, liver cancer, diabetes, and obesity are selected as the target disease target. In the present application, two or more different disease resistance genes as molecular targets can be two or more different disease resistance genes for the same disease, or they can be disease resistance genes belonging to two or more different diseases.

[0089] In this embodiment, two or three disease resistance genes are selected as molecular targets according to the pathological mechanism of the target disease target, and are respectively used as the first molecular target, the second molecular target and the third molecular target. Therefore, the mRNA of the corresponding target needs to be linked and cyclized in the end, so the first molecular target, the second molecular target and the third molecular target are not limited by the difference of disease resistance genes, and randomly represent the molecular target of a disease resistance gene.

[0090] Generally speaking, according to the mRNA sequence of the first molecular target, a first linear DNA template sequence containing the first molecular target is prepared, and the above-mentioned IRES-like pentamer combined translation promoter is linked to the 5' end of the first linear DNA template sequence containing the first molecular target to obtain a second linear DNA template sequence containing the first molecular target as a control drug.

[0091] According to the mRNA sequences of the first molecular target and the second molecular target, a first linear DNA template sequence containing the first molecular target and the second molecular target connected is prepared, and the above-mentioned IRES-like pentamer combined translation promoter is respectively inserted into the 5' end of each of the first linear DNA template sequence containing the first molecular target and the second molecular target to obtain a second linear DNA template sequence containing "IRES-like pentamer combined translation promoter + first molecular target + IRES-like pentamer combined translation promoter + second molecular target";

[0092] According to the mRNA sequences of the first molecular target, the second molecular target and the third molecular target, a first linear DNA template sequence containing the first molecular target, the second molecular target and the third molecular target connected is prepared, and the above-mentioned IRES-like pentamer combined translation promoter is respectively inserted into the 5' end of each of the first linear DNA template sequences containing the first molecular target, the second molecular target and the third molecular target, to obtain a second linear DNA template sequence containing "IRES-like pentamer combined translation promoter + first molecular target + IRES-like pentamer combined translation promoter + second molecular target + IRES-like pentamer combined translation promoter + third molecular target";

[0093] The second linear DNA template sequence is transcribed in vitro to obtain a single linear mRNA; the linear mRNA is cyclized to obtain the translatable circular messenger RNA.

[0094] The preparation method of the above-mentioned translatable circular messenger RNA in the present application can convert any one or more exogenous mRNAs into multi-gene translatable circular mRNAs, which are used to develop nucleic acid drugs for multi-target replacement therapy of mRNA proteins. As a protein replacement therapy strategy, MG-TcmRNA technology has the potential feasibility and reliability to be applied to various different diseases, and provides a new design idea for the preparation of multi-target nucleic acid drugs.

[0095] In one embodiment, after the cyclization treatment, a purification step is further included.

[0096] The embodiments of the present application provide the use of the above-mentioned IRES-like pentamer combined translation promoter or the above-mentioned multi-gene translatable circular messenger RNA in the preparation of nucleic acid drugs.

[0097] The embodiments of the present application provide a multi-target nucleic acid drug, including the above-mentioned multi-gene translatable circular messenger RNA or the multi-gene translatable circular messenger RNA prepared by the preparation method of the above-mentioned multi-gene translatable circular messenger RNA.

[0098] The multi-gene translatable circular mRNA of the present application can efficiently translate and synthesize two or three gene products after being introduced into the cells of an organism, thereby simultaneously supplementing two or three different proteins missing in the disease and obtaining the effect of multi-target drug treatment. Therefore, it can be used to prepare multi-target nucleic acid drugs.

[0099] In one embodiment, the target is heart failure, myocardial infarction, arrhythmia, liver cancer, diabetes or obesity as a target disease target.

[0100] In one embodiment, the multi-target nucleic acid drug is a multi-target nucleic acid drug for treating heart failure, with two or more of ATP2A2, CAND1 or PGC1α as targets.

[0101] Heart failure is a common heart disease and the common result of all different types of heart disease in the later stages. Severe cases can lead to malignant arrhythmias and sudden death. Currently, nucleic acid drugs are widely used in a variety of diseases. Imbalance or disorder of myocardial calcium homeostasis, mitochondrial failure, and myocardial cell death are common characteristics and hallmarks of various types of cardiovascular diseases, and are also one of their pathogenesis. The maintenance of myocardial calcium homeostasis depends on the fine regulation of a regulatory network composed of a series of calcium regulation-related proteins, ion channels, and enzymes. SERCA2a (endoplasmic reticulum calcium ion ATPase, encoding gene ATP2A2) is the most critical protein for maintaining myocardial calcium homeostasis; myocardial regeneration capacity is very weak and is further impaired in the state of heart failure, while apoptosis and other types of cell death increase sharply, resulting in a significant weakening of myocardial contractile function and even loss of blood pumping ability. CAND1 is a recently discovered gene and protein that protects myocardium, prevents cell apoptosis, and promotes myocardial cell regeneration; cell mitochondria are not only the "power plant" of cells, providing energy for myocardial cells to complete various heart functions, but also the "switch" that determines intracellular calcium homeostasis, redox state, and cell death pathways. Abnormal mitochondrial morphology, mitochondrial mold damage, mitochondrial fragmentation, accumulation of oxygen free radicals, intracellular calcium overload, and activation of death pathways are common damage signs of almost all different types of heart disease, especially heart failure. PGC1α can promote the biosynthesis of cardiomyocyte mitochondria, improve cardiomyocyte energy metabolism, reduce cell apoptosis, and increase cardiac contractile function. The use of nucleic acid technology to upregulate the expression level and functional activity of SERCA2a protein encoded by ATP2A2 of cardiomyocyte sarcoplasmic reticulum, the protein encoded by CAND1, and the protein encoded by PGC1α, thereby maintaining calcium homeostasis, mitochondrial homeostasis, and cell homeostasis, is an important factor in maintaining cardiac contraction and electrophysiological activity. Unfortunately, in almost all known cardiovascular diseases, the gene and protein expression levels and functional activities of ATP2A2, CAND1, and PGC1α are significantly decreased, resulting in severe damage to cardiac function. This also lays a theoretical foundation for the replacement therapy of ATP2A2, CAND1, and PGC1α proteins. Combining MG-TcmRNA technology and the importance of ATP2A2, CAND1 and PGC1α, the present application utilizes [ATP2A2+CAND1] or [ATP2A2+CAND1+PGC1α] mRNA sequences to simultaneously supplement SERCA2a, CAND1 and PGC1α multiple proteins to treat cardiovascular diseases.

[0102] In one embodiment, ATP2A2 and CAND1 are used as targets; a nucleic acid drug [ATP2A2+CAND1] / MG-TcmRNA for treating heart failure is designed; it has "IRES-like pentamer combined translation promoter-ATP2A2+IRES-like pentamer combined translation promoter-CAND1"; wherein the sequence of ATP2A2 is the sequence of 544-3567 nts of the coding region of the human ATP2A2 gene (NCBI Reference Sequence: NM_001413013); the sequence of CAND1 is the sequence of 560-4180 nts of the coding region of the human CAND1 gene (NCBI Reference Sequence: NM_001329674.2);

[0103] The ATP2A2 and CAND1 sequences have a polyA tail as shown in SEQ ID NO.7;

[0104] SEQ ID NO.7

[0105] AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA.

[0106] The IRES-like pentamer combined translation promoter and the ATP2A2 sequence are connected via a linker uuuguuuuuuuu.

[0107] In one embodiment, a nucleic acid drug [ATP2A2+CAND1+PGC1α] / MG-TcmRNA for treating heart failure is designed with ATP2A2, CAND1 and PGC1α as targets; it has a structure of "IRES-like pentamer combined translation promoter-ATP2A2+IRES-like pentamer combined translation promoter-CAND1+IRES-like pentamer combined translation promoter-PGC1α"; wherein the sequence of ATP2A2 is the sequence of 544-3567 nts of the coding region of the human ATP2A2 gene (NCBI Reference Sequence: NM_001413013); the sequence of CAND1 is the sequence of 560-4180 nts of the coding region of the human CAND1 gene (NCBI Reference Sequence: NM_001329674.2); the sequence of PGC1α is the sequence of 560-4180 nts of the coding region of the human PGC1alpha gene (NCBI Reference Sequence: NM_001330753.2) coding region 521-2536 nts. The ATP2A2, PGC1α and CAND1 sequences have a polyA tail as shown in SEQ ID NO.7;

[0108] SEQ ID NO.7

[0109] AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA.

[0110] The IRES-like pentamer combined translation promoter and the ATP2A2 sequence are connected via a linker uuuguuuuuuuu.

[0111] After [ATP2A2+CAND1] / MG-TcmRNA or [ATP2A2+CAND1+PGC1α] / MG-TcmRNA is introduced into the cell, it will bind to the ribosome in the cytoplasm and simultaneously initiate the translation process of two proteins [SERCA2a+CAND1] or three proteins [ATP2A2+CAND1+PGC1α], thereby achieving the purpose of replacement therapy of two proteins [SERCA2a+CAND1] or three proteins [SERCA2a+CAND1+PGC1α].

[0112] At the cellular and animal levels, the ability of [ATP2A2+CAND1] / MG-TcmRNA or [ATP2A2+CAND1+PGC1α] / MG-TcmRNA technology to stimulate high expression of two proteins [SERCA2a+CAND1] or three proteins [SERCA2a+CAND1+PGC1α] in cardiomyocytes, as well as its powerful efficacy in protecting against ischemic damage caused by heart failure and improving cardiac function, have been verified.

[0113] It should be noted that, unless otherwise specified or specified, the raw materials involved in the multi-gene translatable circular messenger RNA driven by the IRES-like pentamer combined translation promoter provided in the embodiments of the present invention and its application can all be existing commercially available products; at the same time, unless otherwise specified or specified, the operating steps and parameters involved can all be carried out in the manner disclosed in the prior art or using existing equipment according to its instruction manual, and this application document will not repeat them one by one.

[0114] The following is a further description with reference to specific embodiments.

[0115] Example 1

[0116] This example provides a multi-gene translatable circular messenger RNA driven by an IRES-like pentamer combined translation promoter and its application in the preparation of nucleic acid drugs. Since heart failure is a common heart disease and the final destination of various heart diseases, it can often cause malignant arrhythmias and sudden death. It is taken as a target disease, and three key disease resistance genes ATP2A2, CAND1 and PGC1α are selected as molecular targets. The specific process includes the following:

[0117] (1) Select heart failure as the target;

[0118] (2) Select three key disease resistance genes, ATP2A2, CAND1, and PGC1α, as molecular targets based on the pathological mechanism of the target disease;

[0119] (3) Plasmid construction: Based on the mRNA sequence of ATP2A2, a linear target gene DNA template sequence was prepared, and a T7 promoter sequence was linked to its 5' end, followed by an IRES-like pentamer combined translation promoter, followed by the target gene sequence, and then a BspQ restriction site was linked to the 3' end (for subsequent plasmid linearization). Finally, the entire sequence was constructed on a pUC19 plasmid vector (expression vector) (see SEQ ID NO.7 and SEQ ID NO.8); at the same time, according to the above steps, an ATP2A2 DNA template sequence without an IRES-like pentamer combined translation promoter was designed and prepared as a negative control sequence for protein translation.

[0120] (4) Plasmid amplification and purification: LB liquid medium: 10 g / L tryptone; 5 g / L yeast extract; 10 g / L sodium chloride. Add water to 950 ml, dissolve completely, adjust pH to 7.4 with 5 mol / L NaOH, and finally add water to 1 L. Sterilize with high temperature and high pressure; LB solid medium: 10 g / L tryptone; 5 g / L yeast extract; 10 g / L sodium chloride; 15 g / L agar powder. After sterilization, lower the temperature to 55°C, add antibiotics, and pour the plate immediately. After pouring, open the lid and irradiate with ultraviolet light for 10-15 minutes. Use the Bio-Sky Plasmid Extraction Kit to extract the plasmid, collect 3 ml of bacterial solution (OD600 = 2-4), and you can get 50 μl of 0.1-0.3 mg / ml plasmid.

[0121] (5) Plasmid linearization: NEB BspQⅠ (Cat. No.: R0712S) ⅡS type restriction endonuclease cuts outside the recognition sequence and does not introduce additional sequences (with enzyme and buffer). Agarose gel electrophoresis verifies DNA linearization and ensures full linearization. It efficiently removes restriction endonucleases and modifying enzymes such as ligases, kinases, nucleases, phosphatases, etc., thereby effectively desalting and concentrating DNA samples.

[0122] (6) Based on the mRNA sequences of ATP2A2 and CAND1, a linear DNA template sequence is prepared respectively, and an IRES-like polymer combined translation promoter is linked to each of their 5' ends; at the same time, the ATP2A2 DNA template sequence described in (3)-(5) is used as a control sequence.

[0123] (7) Based on the mRNA sequences of ATP2A2, CAND1 and PGC1α, a linear DNA template sequence is prepared respectively, and an IRES-like polymer combined translation promoter is linked to each of their 5' ends; at the same time, the ATP2A2 DNA template sequence described in (3)-(5) and the ATP2A2+CAND1 DNA template sequence described in (4) are used as control sequences.

[0124] (8) In vitro transcription: The RiboMAXTM Large-Scale RNA Production System-T7 (Promega) was used to perform in vitro transcription from a linear DNA template to synthesize an IRES-like pentamer combined translation promoter / ATP2A2 mRNA (ATP2A2 / TcmRNA) sequence and an ATP2A2-cmRNA sequence.

[0125] (9) The IRES-like pentamer combined translation promoter / ATP2A2 mRNA+CAND1 mRNA ([ATP2A2+CAND1] / TcmRNA) sequence was synthesized by in vitro transcription using the same method as (8).

[0126] (10) Using the same method steps as (8) and (9), in vitro transcription was performed to synthesize the IRES-like pentamer combined translation promoter / ATP2A2 mRNA+CAND1 mRNA+PGC1α mRNA ([ATP2A2+CAND1+PGC1α] / TcmRNA) sequence

[0127] (11) The DNA template was treated with DNase I (at 37°C for 15 min). Then, RNA was purified using an RNA cleanup kit (Zymo).

[0128] (12) In vitro cyclization: In order to make the in vitro synthesized mRNA into a ring, a two-step cyclization method was used (this method has high cyclization efficiency). First, 2mM GTP was added to the reaction product mixture at 55°C for 15 minutes; after RNA column purification, it was incubated at 70°C for 5 minutes, and then placed at 4°C for 3 minutes; Tris-HCl buffer (2mM GTP, 50mM Tris-HCl, 10mM MgCl2, 1mM DTT, pH7.5) was added, and then heated to 70°C for 5 minutes.

[0129] (13) Purification after cyclization: Purify RNA using an RNA cleanup kit (Zymo) and treat with RNase R (at 37°C for 20 min). Column purification is performed again to obtain the product TcmRNA; TcmRNA is dissolved in sterile DEPC water and stored. Specific steps: RNase incubation at 37°C for 15 min, followed by column purification of RNA. 30 μg RNA was heated at 65°C for 3 min (to remove secondary structure) and placed on ice for 3 min; then analyzed by Shimadzu LC-20 series HPLC, using a 7.8×300 mm size - particle size of 3.5 μm, pore size of The purified TcmRNA was purified by using a 4.6×300 mm size exclusion chromatography column (particle size of 5 μm, pore size of 200 angstroms), eluting with RNase-free TE buffer (10 mM Tris, 1 mM EDTA, pH=6.0), and a flow rate of 0.3 ml / min; the purified TcmRNA effluent was collected. TcmRNA was precipitated with 5 M ammonium acetate and then resuspended in enzyme-free water. Finally, three pure TcmRNA sequences were obtained.

[0130] (14) Using lipid nanoparticles (LNPs) (PCM-LNPs) modified with the myocardial-specific targeting peptide PCM (WLSEAGPVVTVRALRGTGSW), three different TcmRNA sequences were encapsulated to construct the myocardial targeted delivery systems of ATP2A2 / TcmRNA, [ATP2A2+CAND1] / TcmRNA, and [ATP2A2+CAND1+PGC1α] / TcmRNA.

[0131] The myocardial targeted delivery system prepared above was experimentally verified in vitro and in vivo.

[0132] In the in vitro experimental verification, cells were directly incubated with three different TcmRNAs encapsulated in PCM-LNP; in the in vivo experimental verification, TcmRNA encapsulated in PCM-LNP was injected into mice through the tail vein. In theory, TcmRNA should be enriched in cardiomyocytes. After ATP2A2 / TcmRNA, [ATP2A2+CAND1] / TcmRNA or [ATP2A2+CAND1+PGC1α] / TcmRNA is introduced into the cell, it will bind to the ribosome in the cytoplasm and initiate the translation process of the corresponding proteins (SERCA2a, CAND1 and PGC1α, respectively), thereby achieving the purpose of SERCA2a, CAND1 and PGC1α protein replacement therapy.

[0133] The experimental process and results are as follows:

[0134] (1) The PCM-LNP TcmRNA prepared in the previous step and its corresponding negative control sequence (a circular cmRNA sequence lacking an IRES-like pentamer combined translation promoter) were transfected into cultured human AC16 cardiomyocytes and mouse primary cardiomyocytes, respectively. Western Blot and Immunocytochemistry were used to detect changes in SERCA2a, CAND1, and PGC1α mRNA and protein levels in cardiomyocytes. The results are shown in Figure 2. Figure 1 shown.

[0135] from Figure 1 It can be seen that 12 hours after transfection with ATP2A2 / TcmRNA, the SERCA2a protein level increased by 3.8 times, and 24 hours later, the SERCA2a protein level increased by 8.5 times ( Figure 1 A); 12 hours after transfection with [ATP2A2+CAND1] / TcmRNA, SERCA2a and CAND1 protein levels increased significantly by 4.9 and 6.2 times, respectively. 24 hours later, SERCA2a and CAND1 protein levels increased by 11.5 and 14.4 times, respectively ( Figure 1 B); 12 hours after transfection with [ATP2A2+CAND1+PGC1α] / TcmRNA, SERCA2a, CAND1 and PGC1α protein levels increased by 6.3-fold, 8.4-fold and 5.8-fold, respectively. 24 hours later, SERCA2a, CAND1 and PGC1α protein levels were upregulated by 13.1-fold, 16.8-fold and 10.5-fold, respectively ( Figure 1 C). In contrast, ATP2A2 / cmRNA lacking an IRES-like pentamer translation promoter did not alter the expression level of any of the proteins ( Figure 1 AC).

[0136] (2) A high afterload heart failure model was established in C57BL / 6 mice by ligating the left anterior descending coronary artery to simulate heart failure caused by hypertension. Then, 10 nM / 1 ml of PCM-LNP ATP2A2 / TcmRNA, ATP2A2 / cmRNA (negative control), [ATP2A2+CAND1] / TcmRNA and [ATP2A2+CAND1+PGC1α] / TcmRNA and its negative control group were injected into the tail vein, and the results of the observations were observed 24 hours later as follows:

[0137] (a) Quantification of mRNA levels of ATP2A2, CAND1, and PGC1α using qRT-PCR Figure 2 As shown; Figure 2In the qRT-PCR RNA quantification results, it was found that relative to the ATP2A2 / cmRNA value, the ATP2A2 mRNA levels in the heart tissues of the three groups of mice treated with different TcmRNAs were upregulated by 4.6 times, 5.8 times, and 4.2 times, respectively, compared with the negative control group after 12 hours. Figure 2 A); CAND1 mRNA levels were upregulated by 4.3 and 5.5 times compared with the negative control group ( Figure 2 B); PGC1α was upregulated by 6.3-fold ( Figure 2 C).

[0138] (b) Western blot analysis was used to semi-quantitate the changes in protein levels of SERCA2a, CAND1, and PGC1α. Figure 3 As shown; Western Blot semi-quantitative analysis revealed that the SERCA2a protein level in myocardial tissue of the ATP2A2 / TcmRNA group was upregulated to 8.2 times the previous level ( Figure 3 D-3F); in the [ATP2A2+CAND1] / TcmRNA group, the SERCA2a protein level was increased to 11.5 times the previous level, and the CAND1 protein level was increased to 13.3 times the previous level; in the [ATP2A2+CAND1+PGC1α] / TcmRNA group, the SERCA2a protein level was increased to 13.5 times the previous level, the CAND1 protein level was increased to 17.7 times the previous level, and the PGC1α was increased to 12.5 times the previous level.

[0139] (c) Representative images of fluorescent immunohistochemistry staining showing the delivery efficiency and subcellular distribution of ATP2A2 / TcmRNA, [ATP2A2+CAND1] / TcmRNA, and [ATP2A2+CAND1+PGC1α] / TcmRNAs constructs. Figure 4 As shown; Immunohistochemical fluorescence staining revealed that ATP2A2 / TcmRNA was enriched in the ribosomes near the nucleus in the cytoplasm, [ATP2A2+CAND1] / TcmRNA was evenly distributed in the cytoplasm, and [ATP2A2+CAND1+PGC1α] / TcmRNA was enriched in the cytoplasm and co-localized with the rod-shaped bodies representing mitochondria ( Figure 4 These results further confirm the in vivo delivery efficiency achieved by PCM-LNPs.

[0140] The above results indicate that ATP2A2 / TcmRNA, [ATP2A2+CAND1] / TcmRNA, and [ATP2A2+CAND1+PGC1α] / TcmRNAs constructs were successfully introduced into cardiomyocytes via lipid nanoparticle-packaged cardiac-specific peptide PCM for cardiac-targeted delivery.

[0141] (d) Echocardiography was used to detect changes in parameters such as fractional shortening (FS%), ejection fraction (EF%), left ventricular end-diastolic diameter (LVIDd), left ventricular end-systolic diameter (LVIDs), left ventricular posterior wall thickness at diastole (LVPWd), and left ventricular wall thickness at systole (LVPWs) to evaluate cardiac function. Figure 5 As shown. In heart failure mice, FS, EF and LVDWT of the above indicators of the hearts of mice that were not treated or treated with ATP2A2 / cmRNA negative control were significantly decreased, while LVIDd and LVIDs were significantly increased. After 12 hours of treatment with ATP2A2 / TcmRNA, [ATP2A2+CAND1] / TcmRNA and [ATP2A2+CAND1+PGC1α] / TcmRNA, FS, EF and LVDWT increased significantly, while LVIDd and LVIDs decreased significantly. The efficacy showed an obvious pattern of [ATP2A2+CAND1+PGC1α] / TcmRNA>>[ATP2A2+CAND1] / TcmRNA>>>ATP2A2 / TcmRNA ( Figure 5 A-5F).

[0142] (e) At the same time, plasma tests found that the levels of heart failure biomarkers CK-MB, cardiac troponin T and troponin I also showed a significant decrease in the same trend.

[0143] (f) The effects of translatable circular RNAs (MG TcmRNAs) ATP2A2 / TcmRNA, [ATP2A2+CAND1] / TcmRNA, and [ATP2A2+CAND1+PGC1α] / TcmRNA on cardiac contractile function and Ca2+ expression in mice with heart failure induced by prolonged transverse aortic constriction (TAC) were evaluated by echocardiography. 2+ The effects of treatment were detected by using acutely isolated cardiomyocytes. Figure 6 As shown, the contractility of myocardial cells (percentage of myocardial fiber shortening) was greatly improved ( Figure 6 A-6B), the intracellular calcium ion level decreased significantly and returned to normal ( Figure 6 C), the instantaneous amplitude of intracellular calcium rises and the rate of decline accelerates ( Figure 6 D), indicating that activation of ATP2A2 transcriptional expression greatly improved intracellular calcium homeostasis. The efficacy showed a significant trend of [ATP2A2+CAND1+PGC1α] / cmRNA>>[ATP2A2+CAND1] / TcmRNA>>>ATP2A2 / TcmRNA. The negative control had no such effect.

[0144] (g) TUNEL kit was used to detect cardiomyocyte apoptosis. The results are shown in Figure 7As shown in the figure, the percentage of cells positive for DNA fragment TUNEL staining decreased, indicating that TcmRNA effectively prevented and inhibited cardiomyocyte apoptosis in heart failure hearts, showing a significant [ATP2A2+CAND1+PGC1α] / TcmRNA>[ATP2A2+CAND1] / TcmRNA>>ATP2A2 / TcmRNA efficacy ( Figure 7-Figure 8 ). The negative control had no such effect.

[0145] (h) Fig. 9 Electron micrographs of impaired cardiac mitochondrial morphology and membrane integrity in a mouse model of heart failure (HF) induced by transverse aortic constriction (TAC). Fig. 9 It can be seen that TcmRNA treatment effectively protected the integrity of mitochondrial morphology and mitochondrial membrane, and showed a significant efficacy of [ATP2A2+CAND1+PGC1α] / TcmRNA>[ATP2A2+CAND1] / TcmRNA>>ATP2A2 / TcmRNA.

[0146] (i) Changes in ejection fraction in a mouse model of heart failure (HF) induced by transverse aortic constriction (TAC) Fig.10 As shown. Fig.10 A-10C shows that in the mouse heart failure model experiment, after treatment with [ATP2A2+CAND1+PGC1α] / TcmRNA>[ATP2A2+CAND1] / TcmRNA>>ATP2A2 / TcmRNA, the ejection fraction (EF%) recovered by 91.2%, 83.7% and 77.3% of the efficacy, respectively, while the effect of the negative control had no statistically and physiologically significant differences compared with the cmRNAs treatment group.

[0147] Therefore, based on the above experimental results, the ability of the obtained ATP2A2 / TcmRNA to stimulate high expression of SERCA2a protein in cardiomyocytes and its strong efficacy in protecting myocardial damage caused by heart failure and improving cardiac function were verified at the cell and animal levels. It was found that the protective effect of [ATP2A2+CAND1+PGC1α] / TcmRNA was higher than that of [ATP2A2+CAND1] / TcmRNA and ATP2A2 / TcmRNA, showing the efficacy of [ATP2A2+CAND1+PGC1α] / TcmRNA>[ATP2A2+CAND1] / TcmRNA>>ATP2A2 / TcmRNA. This shows that MG-TcmRNA technology, as a multi-protein replacement therapy strategy, has the potential feasibility and reliability to be applied to various diseases.

[0148] In summary, the present invention provides a multi-gene translatable circular messenger RNA driven by an IRES-like pentamer combined translation promoter and its application. The present invention organically combines the multi-gene RNA cyclization technology and the IRES-like pentamer for the first time to obtain a multi-gene translatable circular messenger RNA, which does not require chemical modification, reduces the time and economic cost of synthesis / production, avoids mutations introduced by modification, and solves the challenge of linear mRNA drug development. At the same time, the present invention can convert any exogenous mRNA into a translatable circular mRNA, and can be designed to contain a multi-gene translatable circular mRNA according to the key molecular targets of the target disease, for the development of multi-target nucleic acid drugs for mRNA protein therapy, providing a new design idea for the preparation of multi-target nucleic acid drugs. The MG-tcmRNA technology provided by the present invention has at least the following characteristics:

[0149] (1) The core innovation of the MG-TcmRNA technology provided by the present invention includes at least inserting a segment containing a group of IRES-like pentamer translation promoter sequences into the protein-coding mRNA sequence, integrating multi-gene molecular targets for disease targets, and endowing single-gene circular mRNA with 5' cap-independent multi-protein translation capability.

[0150] (2) The MG-TcmRNA technology provided by the present invention can be used as a new strategy and method for multi-protein replacement therapy.

[0151] (3) The therapeutic effect of applying the MG-TcmRNA provided by the present invention is better than that of directly applying the protein.

[0152] (4) The cost of preparing MG-TcmRNA provided by the present invention is much lower than that of synthesizing proteins by biopharmaceutical methods, which is only 25% of the latter. In particular, considering the cost and difficulty of synthesizing polyproteins by biopharmaceutical methods, MG-TcmRNA is more economical and efficient.

[0153] (5) The feasibility, usability and reliability of the two MG-TcmRNAs experimentally verified by the present invention have the potential to be developed into multi-target nucleic acid drugs for clinical application.

[0154] Various embodiments of the present invention may be presented in the form of a range; it should be understood that the description in the form of a range is only for convenience and brevity, and should not be understood as a rigid limitation on the scope of the present invention; therefore, the range description should be considered to have specifically disclosed all possible sub-ranges and single numerical values ​​within the range. For example, the range description from 1 to 6 should be considered to have specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5 and 6, which apply regardless of the range. In addition, whenever a numerical range is indicated herein, it is meant to include any cited number (fractional or integer) within the indicated range.

[0155] Similarly, the number of genes in MG-TcmRNA should not be understood as a rigid limitation on the scope of the present invention, but there must be a limit. Too many genes may cause problems such as reduced transfection efficiency and saturation of protein translation efficiency.

[0156] The above is only a specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any technician familiar with the technical field can easily think of various changes or substitutions within the technical scope disclosed in the present application, which should be included in the protection scope of the present application. Therefore, the protection scope of the present application should be based on the protection scope of the claims.

Claims

1. An IRES-like pentamer combined translation promoter, characterized in that: comprising a first IRES element, a second IRES element, a third IRES element, a fourth IRES element and a fifth IRES element; The first IRES element, the second IRES element, the third IRES element, the fourth IRES element and the fifth IRES element are linked by a linker.

2. An IRES-like pentamer combined translation promoter according to claim 1, characterized in that: The sequence of the first IRES element is shown in SEQ ID NO.1; The sequence of the second IRES element is shown in SEQ ID NO.2; The sequence of the third IRES element is shown in SEQ ID NO.3; The sequence of the fourth IRES element is shown in SEQ ID NO.4; The sequence of the fifth IRES element is shown in SEQ ID NO.5; The length of the linker is 4 nt; preferably, the linker is uuug; The sequence of the IRES-like pentamer combined translation promoter is shown in SEQ ID NO.

6.

3. A multi-gene translatable circular messenger RNA, characterized in that: It comprises a circular messenger RNA, wherein the IRES-like pentamer combined translation promoter according to claim 1 or 2 is inserted before the 5' end of the circular messenger RNA sequence.

4. A multi-gene translatable circular messenger RNA according to claim 3, characterized in that: The translatable circular messenger RNA comprises circular messenger RNA composed of mRNAs of two or more different genes; preferably, the number of the different genes is 2 or 3.

5. A method for preparing multi-gene translatable circular messenger RNA, characterized in that: The following steps are involved: Select two or more different disease resistance genes as molecular targets according to the pathological mechanism of the target disease; According to the mRNA sequence of each of the molecular targets, respectively prepare the corresponding first linear DNA template sequence, and link the IRES-like pentamer combined translation promoter according to claim 1 or 2 to the 5' end of each of the first linear DNA template sequences; Two or more first linear DNA template sequences containing IRES-like pentamer combined translation promoters are connected into a second linear DNA template sequence by a linker, and the second linear DNA template sequence is transcribed in vitro to obtain a single linear mRNA; the linear mRNA is cyclized to obtain the multi-gene translatable circular messenger RNA.

6. Use of the IRES-like pentamer combined translation promoter according to claim 1 or 2 or the multi-gene translatable circular messenger RNA according to any one of claims 3 to 5 in the preparation of nucleic acid drugs.

7. A multi-target nucleic acid drug, characterized in that: The invention comprises the multi-gene translatable circular messenger RNA as described in claim 3 or 4, or comprises the multi-gene translatable circular messenger RNA prepared by the preparation method of the multi-gene translatable circular messenger RNA as described in claim 5.

8. The multi-target nucleic acid drug according to claim 7, characterized in that: The target is heart failure, myocardial infarction, arrhythmia, liver cancer, diabetes or obesity as the target disease target.

9. The multi-target nucleic acid drug according to claim 7, characterized in that: The multi-target nucleic acid drug is a multi-target nucleic acid drug for treating heart failure, with two or more of ATP2A2, CAND1 or PGC1α as targets.

10. The multi-target nucleic acid drug according to claim 9, characterized in that: ATP2A2 and CAND1 are used as targets; the multi-target nucleic acid drug for treating heart failure has a structural sequence of IRES-like pentamer combined translation promoter-ATP2A2-IRES-like pentamer combined translation promoter-CAND1; With ATP2A2, CAND1 and PGC1α as targets, the nucleic acid drug for treating heart failure has a structural sequence of IRES-like pentamer combined translation promoter-ATP2A2-IRES-like pentamer combined translation promoter-CAND1-IRES-like pentamer combined translation promoter-PGC1α.